Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML

Documenti analoghi

• Comparative Analysis of ICC and WHO Classifications Reveals Molecular and Clinical Convergence Between AML‐MR and MDS/AML
  di: Yanhui Wei, et al.
  Pubblicazione: (2026)
• Distinctive Molecular Risk Factors Between MDS and MDS / AML Defined by ICC
  di: Ting‐juan Zhang, et al.
  Pubblicazione: (2026)
• Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside Analogs
  di: Erwann Collomb, et al.
  Pubblicazione: (2025)
• Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain
  di: Pashna N. Munshi, et al.
  Pubblicazione: (2024)
• Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
  di: Marina Konopleva, et al.
  Pubblicazione: (2026)